• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿托伐他汀在应激条件下的降解动力学及 HPLC 化学分析。

Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC.

机构信息

University Center of the North of Espirito Santo, UFES, BR 101 North, km 60, 29932-540 São Mateus, ES, Brazil.

出版信息

Molecules. 2013 Jan 24;18(2):1447-56. doi: 10.3390/molecules18021447.

DOI:10.3390/molecules18021447
PMID:23348997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6270390/
Abstract

Atorvastatin is an antilipemic drug belonging to the statins class, whose reference drug is Pfizer's Lipitor®. It is used to reduce the levels of lipoproteins rich in cholesterol and reduce the risk of coronary artery disease. It is well-known that calcium atorvastatin (ATV), C₆₆H₆₈CaF₂N₄O₁₀•3H₂O, presents polymorphism. The drug in question is commonly sought after by pharmaceutical industries that produce generic drugs, due to the fact that the drug has a high value price, it is consumed globally, and its patent expired in late 2010. Many questions concerning this drug's pharmaceutical scope demonstrate its importance regarding stability studies and the identification of degradation products of drugs and pharmaceutical formulations. ATV has been found to degrade under acid and basic conditions, including a first order kinetic degradation under acid conditions, as compared to a zero order kinetic degradation under basic conditions, which tends to be less stable when studied within acid mediums. The rate constant (k) for degradation in acid medium was 1.88 × 10⁻² s⁻¹ (first order), while for basic medium k = 2.35 × 10⁻⁴ mol L⁻¹ s⁻¹ (zero order), demonstrating a lower stability of the drug within acid mediums.

摘要

阿托伐他汀是一种降脂药物,属于他汀类药物,其参比药物是辉瑞的立普妥®。它用于降低富含胆固醇的脂蛋白水平,降低冠心病的风险。众所周知,钙阿托伐他汀(ATV),C₆₆H₆₈CaF₂N₄O₁₀·3H₂O,具有多晶型性。生产仿制药的制药公司通常会寻找这种药物,因为这种药物价格高,在全球范围内使用,其专利已于 2010 年底到期。许多关于该药物药物范围的问题表明,它在稳定性研究和药物及药物制剂降解产物的鉴定方面非常重要。ATV 在酸性和碱性条件下会降解,包括在酸性条件下的一级动力学降解,而在碱性条件下的零级动力学降解,在酸性介质中研究时往往不太稳定。在酸性介质中降解的速率常数(k)为 1.88×10⁻² s⁻¹(一级),而在碱性介质中 k = 2.35×10⁻⁴ mol L⁻¹ s⁻¹(零级),表明药物在酸性介质中的稳定性较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/6d93de361ce6/molecules-18-01447-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/2aef686bc6af/molecules-18-01447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/ff300ec2da56/molecules-18-01447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/1507166fd6c5/molecules-18-01447-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/f60438713257/molecules-18-01447-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/0a6b50685933/molecules-18-01447-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/e48bd7549b61/molecules-18-01447-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/6d93de361ce6/molecules-18-01447-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/2aef686bc6af/molecules-18-01447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/ff300ec2da56/molecules-18-01447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/1507166fd6c5/molecules-18-01447-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/f60438713257/molecules-18-01447-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/0a6b50685933/molecules-18-01447-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/e48bd7549b61/molecules-18-01447-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8108/6270390/6d93de361ce6/molecules-18-01447-g007.jpg

相似文献

1
Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC.阿托伐他汀在应激条件下的降解动力学及 HPLC 化学分析。
Molecules. 2013 Jan 24;18(2):1447-56. doi: 10.3390/molecules18021447.
2
Stability indicating RP-HPLC method for simultaneous determination of atorvastatin and amlodipine from their combination drug products.用于同时测定阿托伐他汀和氨氯地平复方制剂中二者含量的稳定性指示反相高效液相色谱法。
Chem Pharm Bull (Tokyo). 2007 Feb;55(2):241-6. doi: 10.1248/cpb.55.241.
3
Isolation and structure determination of oxidative degradation products of atorvastatin.阿托伐他汀氧化降解产物的分离与结构鉴定。
J Pharm Biomed Anal. 2009 Dec 5;50(5):729-36. doi: 10.1016/j.jpba.2009.06.008. Epub 2009 Jun 12.
4
Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase.用于测定片剂中阿托伐他汀及监测其在固相中稳定性的高效液相色谱法的验证
Acta Pol Pharm. 2006 Nov-Dec;63(6):471-6.
5
Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of atorvastatin and ezetimibe from their combination drug products.用于同时测定阿托伐他汀和依折麦布复方制剂中两者含量的稳定性指示反相液相色谱法。
J AOAC Int. 2007 Nov-Dec;90(6):1539-46.
6
Stability-indicating high-performance liquid chromatographic assay of atorvastatin with fluorescence detection.采用荧光检测的阿托伐他汀稳定性指示高效液相色谱法测定
J AOAC Int. 2007 Nov-Dec;90(6):1547-53.
7
Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe.采用超高效液相色谱法开发并验证阿托伐他汀和依折麦布固定剂量复方制剂的稳定性指示测定方法。
J Chromatogr Sci. 2013 Mar;51(3):222-8. doi: 10.1093/chromsci/bms131. Epub 2012 Aug 3.
8
Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets.用于同时测定片剂中阿托伐他汀、非诺贝特及其降解产物的稳定性指示超高效液相色谱法
J Pharm Biomed Anal. 2008 Sep 10;48(1):120-6. doi: 10.1016/j.jpba.2008.05.018. Epub 2008 May 21.
9
Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets.高效液相色谱法和毛细管电泳法用于同时测定片剂中氨氯地平和阿托伐他汀及其酸性降解产物的方法的开发与验证
Acta Pharm. 2016 Dec 1;66(4):479-490. doi: 10.1515/acph-2016-0040.
10
Estimation of atorvastatin calcium and fenofibrate in tablets by derivative spectrophotometry and liquid chromatography.采用导数分光光度法和液相色谱法测定片剂中阿托伐他汀钙和非诺贝特的含量。
J AOAC Int. 2007 May-Jun;90(3):700-5.

引用本文的文献

1
Spectroscopic studies on photodegradation of atorvastatin calcium.阿托伐他汀钙光降解的光谱研究。
Sci Rep. 2021 Jul 28;11(1):15338. doi: 10.1038/s41598-021-94693-5.
2
Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms.用于3D打印控释剂型开发的超临界流体技术
Pharmaceutics. 2021 Apr 13;13(4):543. doi: 10.3390/pharmaceutics13040543.
3
The potential of Atorvastatin for chronic lung diseases therapy.阿托伐他汀用于慢性肺病治疗的潜力。

本文引用的文献

1
Thermal behavior study and decomposition kinetics of amiodarone hydrochloride under isothermal conditions.盐酸胺碘酮在等温条件下的热行为研究及分解动力学。
Drug Dev Ind Pharm. 2011 Jun;37(6):638-47. doi: 10.3109/03639045.2010.534099. Epub 2011 Mar 30.
2
Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples.商用结晶态和非晶态阿托伐他汀钙样品的固态特性研究。
AAPS PharmSciTech. 2010 Jun;11(2):598-609. doi: 10.1208/s12249-010-9419-7. Epub 2010 Mar 30.
3
Crystal forms of atorvastatin.阿托伐他汀的晶体形式
Saudi Pharm J. 2020 Nov;28(11):1353-1363. doi: 10.1016/j.jsps.2020.08.025. Epub 2020 Sep 12.
4
Atorvastatin lipid nanocapsules and gold nanoparticles embedded in injectable thermo-gelling hydrogel scaffold containing adipose tissue extracellular matrix for myocardial tissue regeneration.阿托伐他汀脂质纳米囊和金纳米粒子嵌入富含脂肪组织细胞外基质的可注射温敏水凝胶支架用于心肌组织再生。
IET Nanobiotechnol. 2019 Dec;13(9):933-941. doi: 10.1049/iet-nbt.2019.0035.
5
Characterization of two new degradation products of atorvastatin calcium formed upon treatment with strong acids.阿托伐他汀钙经强酸处理后形成的两种新降解产物的表征。
Beilstein J Org Chem. 2019 Sep 2;15:2085-2091. doi: 10.3762/bjoc.15.206. eCollection 2019.
6
Superior Stability of Hydroxysafflor Yellow A in Xuebijing Injection and the Associated Mechanism.血必净注射液中羟基红花黄色素 A 的稳定性及其机制。
Molecules. 2017 Dec 2;22(12):2129. doi: 10.3390/molecules22122129.
7
Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels.阿托伐他汀治疗心房颤动可降低血清高敏C反应蛋白水平。
Biomed Res Int. 2015;2015:402481. doi: 10.1155/2015/402481. Epub 2015 Jul 1.
Arch Pharm Res. 2009 Jun;32(6):933-6. doi: 10.1007/s12272-009-1616-0. Epub 2009 Jun 26.